Advancing Care Coordination Between Cancer and Primary Care Teams for Complex Cancer Survivors

Part of paid clinical trials in New Brunswick, New Jersey.

Sponsor
Rutgers, The State University of New Jersey
Study ID
NCT06834204
Status
Enrolling By Invitation

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • PC2: Primary Care Connect — OTHER
    Primary Care Connect is a health system intervention that includes patient education, electronic medical record optimization, protocolized communication from cancer care team to primary care.

Study Details

The purpose of this randomized clinical trial is to learn if 'complex' cancer patients who receive care guided by a health system intervention, Primary Care Connect (PC2) have their risks of cardiovascular disease (CVD) managed better than those who receive usual care. This study focuses on "complex" cancer survivors who have higher CVD risk when diagnosed with cancer because they also have had a diagnosis of 1 or more chronic conditions (e.g., hypertension, diabetes, and/or hyperlipidemia) requiring medication management. This study also aims to learn about the ease of implementing the health system intervention from the perspectives of cancer teams, primary care teams, and complex cancer patients. The main questions the study aims to answer are: * Do patients enrolled in the PC2 arm remain connected to their primary care teams during active cancer treatment for chronic disease management compared to patients in usual care? * Do patients enrolled in the PC2 arm have better management of their chronic conditions during active cancer treatment compared to patients in usual care? * How do the care team and patients experience this change in care delivery related to their work and care experiences? This study will compare complex cancer survivors who receive care according to the PC2 intervention to usual care to see if PC2 works to improve cardiovascular risk management. Participants will: * receive educational materials about the study upon enrollment * complete on-line or written surveys at 4 times * Visit the clinic for check ups and test related to the study 4 times

Key Dates

First listed
Feb 19, 2025
Start date
Apr 24, 2026
Status verified
Jul 2026
Primary completion
Jul 1, 2028
Completion
Apr 30, 2029

Study Design

Enrollment
266 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH

Arms

  • No Intervention: Usual Care
    Patients in this arm will not receive the intervention.
  • Experimental: Primary Care Connect (PC2)
    Patients enrolled in this arm will be provided print and video educational materials about the importance of shared care to manage existing and prevent exacerbations in chronic disease management. Additionally, their cancer care team will provide a brief protocolized communication to their primary care team that explain how their initial treatment may impact chronic disease management, clarifying the primary care role during acute treatment, and providing contact information for cancer team. Primary care providers of patients enrolled in this arm will receive an outreach packet that includes information provided in print and short video to explain the rationale of the intervention and the materials provided by the cancer care team.

Primary Outcome Measure

Connected Care-Continuity with Primary Care Provider [ Time Frame: From the time of enrollment to 18-months post enrollment. ]

Locations (1)

FacilityCityStateZIPSite coordinators
Rutgers Cancer InstituteNew BrunswickNew Jersey08901-

Find similar trials in New Brunswick, NJ

Nationwide
Bladder cancer trialsEndometrial cancer trialsHypertension (high blood pressure) trialsOncology trialsUrology trialsGynecologic oncology trialsWomen's health trialsCardiology trialsHeart disease trials
By condition
Bladder cancerEndometrial cancerHypertension (high blood pressure)
By specialty
OncologyUrologyGynecologic oncologyWomen's healthCardiologyHeart disease
By research site
Rutgers Cancer Institute· New Brunswick, NJ

Related Studies